Are We Ready to Translate T-Cell Transmigration in Stroke?

Wolf-Rüdiger Schäbitz, MD; Ulrich Dirnagl, MD

Stroke research is plagued by failed bench to bedside solution—hundreds of agents that protected rodent brains were not effective when tested in clinical trials.\(^6\) Low reproducibility and predictiveness seem to be hallmarks of preclinical studies in many fields of medicine. It is becoming increasingly clear that, at least partially, low internal and external validity (lack of randomization and blinding, young animals lacking comorbidities), lack of power (small sample sizes), and negative publication bias are to be blamed, because they lead to inflated effect sizes or false-positive results. In the context of the many failures of neuroprotection trials in stroke, it is surprising on how little evidence the ongoing natalizumab stroke trial is based. The negative results of the study by Langhauser et al\(^3\) add further doubt concerning the robustness of this treatment strategy.

It is clear that individual laboratories do not have the resources or incentives to replicate their own or other’s data and to preclinically test novel treatments with the required sample sizes and portfolio of models. This can only be done by international consortia of researchers, acting in a concerted fashion.\(^11\) Some methodological aspects of such preclinical phase III studies can be borrowed from clinical trials; others still need to be developed (eg, European Union–funded Multicenter Preclinical Animal Research Team; http://www.multi-part.org). It is interesting to note that an international consortium coordinated by Arthur Liesz (Munich, Germany) is currently conducting such a preclinical phase III trial for the CD49d antibody, involving laboratories from Germany, France, Italy, and Spain. Results of this trial will be available soon and hopefully help to resolve the issue whether T-cell transmigration is ready for translation. We sincerely hope that natalizumab will not join the list of drugs for which experimental studies delivered ex post evidence why the clinical trial had failed (eg, the German erythropoietin [EPO] trial,\(^12\) the Abciximab Emergent Stroke Treatment [ABESST] II trial,\(^13\) the enlimomab trial).\(^14\)

**Disclosures**

None.

**References**


**Correspondence** to Wolf-Rüdiger Schäbitz, MD, Neurologie, EvKB-Bethel, Burgsteig 13, 33617 Bielefeld, Germany. E-mail wolf.schaebitz@evkb.de


**References**


**Disclosures**

None.


Key Words: inflammation • integrin alpha4 • stroke
Are We Ready to Translate T-Cell Transmigration in Stroke?
Wolf-Rüdiger Schäbitz and Ulrich Dirnagl

Stroke. published online April 17, 2014;
Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2014 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/early/2014/04/17/STROKEAHA.114.005294.citation

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Stroke can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Stroke is online at:
http://stroke.ahajournals.org/subscriptions/